News AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncol... Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at AACR 2025.
News MaaT microbiota drug shows survival advantage in GvHD MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access pro
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.